📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. (2017)

First Author: Weber J

Attributed to: MICA: Immunotherapy for oral cancer prevention and treatment funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1056/nejmoa1709030

PubMed Identifier: 28891423

Publication URI: http://europepmc.org/abstract/MED/28891423

Type: Journal Article/Review

Volume: 377

Parent Publication: The New England journal of medicine

Issue: 19

ISSN: 0028-4793